Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Transfusion

• Publication date

  2003-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1537-2995.2003.00418.xPMID 12757525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets

  2002cited by this paper
• Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions.

  2002cited by this paper
• Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.

  2001cited by this paper
• Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cited by this paper
• Lowering the Prophylactic Platelet Transfusion Threshold: a Prospective Analysis

  2001cited by this paper
• Nonparametric Analysis of Recurrent Events and Death

  2000cited by this paper
• Extensions and Applications of Event Charts

  2000cited by this paper
• A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets

  1999cited by this paper
• Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double‐blind trial

  1999cited by this paper
• Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.

  1998cited by this paper
• Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.

  1998cited by this paper
• Platelet transfusion: a dose-response study.

  1998cited by this paper
• Prophylactic platelet transfusions in acute myeloid leukemia.

  1998cited by this paper
• Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.

  1997cited by this paper
• Marginal analysis of recurrent events and a terminating event.

  1997cited by this paper
• The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

  1997cited by this paper
• Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution.

  1996cited by this paper
• Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.

  1991influential reference
• Health Measurement Scales: A practical guide to thier development and use

  1989cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.

  1962cited by this paper

• INTERNATIONAL NORMALIZED RATIO AND ACTIVATED PARTIAL THROMBOPLASTIN TIME DO NOT PREDICT PLASMA TRANSFUSION IN LIVER TRANSPLANTATION

  2025cites this paper
• Assessment of platelet indices, beta-thromboglobulin and platelet factor IV in platelet concentrate at University of Ilorin Teaching Hospital, Nigeria

  2025cites this paper
• What counts as patient-important upper gastrointestinal bleeding in the ICU? A mixed-methods study protocol of patient and family perspectives

  2023cites this paper
• How I use platelet transfusions.

  2022cites this paper
• Bleeding in Critically Ill Children—Review of Literature, Knowledge Gaps, and Suggestions for Future Investigation

  2021cites this paper
• Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice

  2021cites this paper
• Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology

  2021cites this paper
• Romiplostim for Primary Immune Thrombocytopenia in Routine Clinical Practice: Results from a Multicentre Observational Study in Germany

  2021cites this paper
• Exploring the components of bleeding outcomes in transfusion trials for patients with hematologic malignancy

  2020cites this paper
• Bleeding assessment and bleeding severity in thrombocytopenic patients undergoing invasive procedures

  2020cites this paper
• PLATON: use of romiplostim to treat chronic primary immune thrombocytopenia

  2020cites this paper
• Platelet Transfusion Medicine

  2019cites this paper
• Bleeding Assessment Scale in Critically Ill Children (BASIC): Physician-Driven Diagnostic Criteria for Bleeding Severity.

  2019cites this paper
• Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.

  2018cites this paper
• A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice

  2017cites this paper
• Platelet Transfusion Practices in the ICU: Data From a Large Transfusion Registry.

  2016cites this paper
• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.

  2016cites this paper
• Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia

  2016cites this paper
• Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

  2015cites this paper
• Thrombopoiesis‐stimulating agents and myelodysplastic syndromes

  2015cites this paper
• Exames convencionais da coagulação como variáveis preditoras da indicação de transfusão de plasma fresco congelado durante o transplante de fígado

  2015cites this paper
• A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

  2015cites this paper
• Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction.

  2015cites this paper
• Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review

  2015cites this paper
• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

  2015cites this paper
• Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

  2014cites this paper
• Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

  2014cites this paper
• Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

  2014cites this paper
• Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

  2014cites this paper
• Safety and efficacy of thrombopoietin‐receptor agonists in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials

  2014cites this paper
• Prophylactic platelet transfusions: should they be a treatment of the past?

  2014cites this paper
• Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

  2014cites this paper
• A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation.

  2014cites this paper
• Statistical Methods for Life History Analysis Involving Latent Processes

  2014cites this paper
• Inverse probability weighted estimating equations for randomized trials in transfusion medicine

  2013cites this paper
• The influence of bleeding on trigger changes for platelet transfusion in patients with chemotherapy‐induced thrombocytopenia

  2013cites this paper
• A dynamic Mover–Stayer model for recurrent event processes subject to resolution

  2013cites this paper
• Platelet Transfusion Threshold in Patients With Upper Gastrointestinal Bleeding: A Systematic Review

  2012cites this paper
• Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia

  2012cites this paper
• Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

  2012cites this paper
• Meta‐analysis of the studies of bleeding complications of platelets pathogen‐reduced with the Intercept system

  2012cites this paper
• Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta‐analysis of randomized controlled trials

  2012cites this paper
• Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study.

  2012cites this paper
• A new tool to assess bleeding severity in patients with chemotherapy‐induced thrombocytopenia (CME)

  2012cites this paper
• The observation of bleeding complications in haemato‐oncological patients: stringent watching, relevant reporting

  2012cites this paper
• Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.

  2012cites this paper
• Original article SelectivevalidationoftheWHOBleedingScalein patients with chronic immune thrombocytopenia

  2012cites this paper
• Thrombocytopenia, bleeding, and use of platelet transfusions in sick neonates.

  2012cites this paper
• Factors determining the risk of severe (WHO grades 3 and 4) hemorrhage in hematologic patients.

  2011cites this paper
• Time to rethink clinically important outcomes in platelet transfusion trials

  2011cites this paper
• Bias in transfusion research: from study design to result reporting

  2011cites this paper
• Platelet transfusions for patients with haematological malignancies: who needs them?

  2011cites this paper
• Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters

  2011cites this paper
• EVALUATION OF PLATELET TRANSFUSION TRIGGERS

  2011cites this paper
• Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia

  2011cites this paper
• Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges

  2011cites this paper
• OF PLATELET TRANSFUSION TRIGGERS

  2011cites this paper
• The randomized controlled trial: in celebration of TRANSFUSION's 50th

  2010cites this paper
• Platelet dose for prophylactic platelet transfusions

  2010cites this paper
• Dose of prophylactic platelet transfusions and prevention of hemorrhage.

  2010cites this paper
• Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions.

  2010cites this paper
• Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura.

  2010cites this paper
• Prospective, Observational Study of Outcomes in Neonates With Severe Thrombocytopenia

  2009cites this paper
• The clinical impact of platelet refractoriness: correlation with bleeding and survival

  2008cites this paper
• Controversy concerning platelet dose

  2007cites this paper
• Chapter 27 – Virus-Safe Products: Pathogen Reduction and Inactivation

  2007cites this paper
• Bleeding during critical illness: a prospective cohort study using a new measurement tool.

  2007cites this paper
• Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 × 109 or 20 × 109 per L

  2007cites this paper
• Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma‐clotting proteins

  2007cites this paper
• A multicenter pilot‐randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation

  2007cites this paper
• Appraisal of the evidence for the clinical use of FFP and plasma fractions.

  2006cites this paper
• Feasibility and usefulness of self‐assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding

  2006cites this paper
• Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses

  2006cites this paper
• Design issues with clinical experimental platelet transfusion studies

  2006cites this paper
• A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia

  2006cites this paper
• A study of the agreement between patient self‐assessment and study personnel assessment of bleeding symptoms

  2006cites this paper
• Assessing the effectiveness of whole blood–derived platelets stored as a pool: a randomized block noninferiority trial

  2005cites this paper
• Hydrocortisone in septic shock: too much, too little, too soon?

  2005cites this paper
• Fresh frozen plasma: friend or faux pas in critical illness?

  2005cites this paper
• Current methods of assessing platelet function: relevance to transfusion medicine

  2005cites this paper
• Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction.

  2005cites this paper
• Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?

  2005cites this paper
• Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross‐matching locally available platelet products

  2004cites this paper
• Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation.

  2004cites this paper
• Pathogen reduction technologies: what are the concerns?

  2004cites this paper
• Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials

  2004cites this paper
• How much do we know about the platelet transfusion threshold?

  2003cites this paper
• Role of the Hct in the treatment of thrombocytopenic patients

  2003cites this paper